Steroids decrease efficacy of PD-1/PD-L1 inhibitors in NSCLC

Dr. Matthew Stenger, via The ASCO Post:

In a study reported in the Journal of Clinical Oncology, Arbour et al found that baseline treatment with corticosteroids was associated with poorer efficacy of programmed cell death protein 1 (PD-1) or programmed death cell ligand 1 (PD-L1) inhibitors in patients with non–small cell lung cancer (NSCLC).

Furthermore,

The investigators concluded, “Baseline corticosteroid use of ≥ 10 mg of prednisone equivalent was associated with poorer outcome in patients with non–small cell lung cancer who were treated with [PD-1/PD-L1] blockade.”

Baseline corticosteroids were associated with decreased overall response rate, progression-free survival, and overall survival with PD-(L)1 blockade.

What's the clinical impact for oncologists? Must we then avoid corticosteroids entirely? The authors recommend its "prudent" use.

Comments

Popular posts from this blog

Afternoons at home

Life happened

Once upon an island